Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam D Cohen

Showing results (21-30 of 108) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2019
How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple MyelomaAdam D Cohen, Noopur Raje, Jessica A Fowler, et al.
Hematology/Oncology Clinics of North America|December 29, 2023
Chimeric Antigen Receptor T Cells in the Treatment of Multiple MyelomaZainul S Hasanali, Beatrice Razzo, Sandra P Susanibar-Adaniya, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 9, 2021
Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With EculizumabCraig W Freyer, Erin M Bange, Sarah Skuli, et al.
Clinical Case Reports|November 13, 2023
Multiple airway plasmacytomas: A rare cause of proximal airway obstruction requiring tumor debulkingChristopher Ghiathi, Ashley N Barlev, Gabriel C Caponetti, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 16, 2024
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual MeetingNoopur S Raje, Adam D Cohen, Krina K Patel, et al.
Blood Advances|August 28, 2019
Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapiesAdam D Cohen, Alfred L Garfall, Ahmet Dogan, et al.
The Lancet. Haematology|December 22, 2015
Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot studyScott F Huntington, Brendan M Weiss, Dan T Vogl, et al.
The Journal of Experimental Medicine|May 6, 2009
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosisDaniel Hirschhorn-Cymerman, Gabrielle A Rizzuto, Taha Merghoub, et al.
Blood Cancer Journal|April 28, 2026
Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case seriesSandra Susanibar-Adaniya, Benjamin A Derman, Adam D Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2015
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple MyelomaDon M Benson, Adam D Cohen, Sundar Jagannath, et al.
Pageof 11

Showing results (21-30 of 108) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2019
How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple MyelomaAdam D Cohen, Noopur Raje, Jessica A Fowler, et al.
Hematology/Oncology Clinics of North America|December 29, 2023
Chimeric Antigen Receptor T Cells in the Treatment of Multiple MyelomaZainul S Hasanali, Beatrice Razzo, Sandra P Susanibar-Adaniya, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 9, 2021
Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With EculizumabCraig W Freyer, Erin M Bange, Sarah Skuli, et al.
Clinical Case Reports|November 13, 2023
Multiple airway plasmacytomas: A rare cause of proximal airway obstruction requiring tumor debulkingChristopher Ghiathi, Ashley N Barlev, Gabriel C Caponetti, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 16, 2024
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual MeetingNoopur S Raje, Adam D Cohen, Krina K Patel, et al.
Blood Advances|August 28, 2019
Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapiesAdam D Cohen, Alfred L Garfall, Ahmet Dogan, et al.
The Lancet. Haematology|December 22, 2015
Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot studyScott F Huntington, Brendan M Weiss, Dan T Vogl, et al.
The Journal of Experimental Medicine|May 6, 2009
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosisDaniel Hirschhorn-Cymerman, Gabrielle A Rizzuto, Taha Merghoub, et al.
Blood Cancer Journal|April 28, 2026
Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case seriesSandra Susanibar-Adaniya, Benjamin A Derman, Adam D Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2015
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple MyelomaDon M Benson, Adam D Cohen, Sundar Jagannath, et al.
Pageof 11